ClinicalTrials.gg
CompletedNCT02608073Updated Mar 2, 2016

A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

A Phase 2 interventional study of Capecitabine and Cisplatin in Nasopharyngeal Cancer, sponsored by Hoffmann-La Roche. Completed at 9 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-03-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing cisplatin in Nasopharyngeal Neoplasms — 2 open to participants now, 3 under way, 1 of them phase 3. Cisplatin · Nasopharyngeal Neoplasms.

Enrollment
13th of 17
45 · median 51
Started
2004
the only one that year
Phase 2
10 of 18
1 open now
Registered
13th of 18
by date
Lead sponsor
1 of 18
Hoffmann-La Roche

Among the 18 studies testing cisplatin in Nasopharyngeal Neoplasms, this one is the 13th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2004, is one of 10 in phase 2, and was the 13th registered.

Nasopharyngeal Neoplasms

226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.

Browse Nasopharyngeal Neoplasms studies →

Open to participants now

2 of the 18 studies testing cisplatin in Nasopharyngeal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing cisplatin in Nasopharyngeal Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, tolerability, and effect on quality of life of oral capecitabine in combination with intravenous (IV) cisplatin in participants with metastatic nasopharyngeal cancer. Participants will receive up to 8 cycles of capecitabine treatment, and cisplatin will be administered on the first day of each cycle. The anticipated time on study treatment is up to 24 weeks, and the target sample size is 44 individuals.

03

Conditions studied

  • Nasopharyngeal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 to 75 years of age
  • confirmed, poorly differentiated or undifferentiated nasopharyngeal cancer with at least 1 which has not been irradiated
  • Ability to swallow and retain oral medication

Exclusion criteria

Exclusion Criteria:

  • Previous cytotoxic chemotherapy except adjuvant, concurrent, or treatment completed at least 6 months before enrollment
  • cardiac disease
  • History of other within the last 5 years except cured basal cell cancer of the skin or cured cancer in situ of the cervix
  • Radiotherapy within 4 weeks of treatment start or any prior radiotherapy performed to the indicator lesion(s) being measured in the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Capecitabine + Cisplatin

    Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square \[mg/m\^2\] tablets twice daily \[BID\] orally) and cisplatin (100 mg/m\^2/day intravenous \[IV\] infusion) for up to 8 cycles.

    Drug: Capecitabine · Drug: Cisplatin

Interventions

  • Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).

    Also known as: Xeloda

  • Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Time frame: up to 28 days after the last intake of study treatment (up to approximately 5 years)

Secondary outcomes

  1. Overall survival

    Time frame: Up to approximately 18 months

  2. Time to disease progression

    Time frame: Up to approximately 18 months

  3. Duration of response

    Time frame: Up to approximately 18 months

  4. Complete response rate

    Time frame: Up to approximately 18 months

  5. Incidence of adverse events

    Time frame: Up to approximately 7 months

  6. Quality of life according to Visual Analog Scale (VAS) score

    Time frame: Up to approximately 6 months

  7. Treatment convenience/satisfaction according to VAS score

    Time frame: Up to approximately 6 months

07

Study locations

9 sites
  • Hong Kong, 852, Hong Kong
  • Hong Kong, Hong Kong
  • Jogjakarta, 55284, Indonesia
  • Kuala Lumpur, 50603, Malaysia
  • Kueishan, 333, Taiwan
  • Taipei, 00112, Taiwan
  • Taipei, 106, Taiwan
  • Bangkok, 10330, Thailand
  • Bangkok, 10400, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2015
First posted
Nov 18, 2015
Start
Nov 2004
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Last update
Mar 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02608073
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
Nov 2004
Primary completion
Nov 2009
Completion
Nov 2009
Last update
Mar 2, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Cisplatin

Start the discussion